"bladder cancer" trang 2 - tải miễn phí từ tailieunhanh
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer

Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer
9    83    1
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier

Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier
18    83    1
Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway

Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway
8    97    0
Down-regulation of A-FABP predicts nonmuscle invasive bladder cancer progression: Investigation with a long term clinical follow-up

Down-regulation of A-FABP predicts nonmuscle invasive bladder cancer progression: Investigation with a long term clinical follow-up
13    55    1
The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells

The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells
12    44    1
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: A Markov model

Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: A Markov model
8    39    1
Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
8    69    1
Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: A retrospective non-randomized comparative study

Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: A retrospective non-randomized comparative study
11    50    1
Characteristics and clinical significance of CD163+/CD206+M2 mono-macrophage in the bladder cancer microenvironment

Characteristics and clinical significance of CD163+/CD206+M2 mono-macrophage in the bladder cancer microenvironment
9    39    1
Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: A multicenter retrospective study

Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: A multicenter retrospective study
8    26    1
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
15    4    1
Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014

Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014
11    59    1
Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholineco-n-butyl methacrylate) in an orthotopic bladder cancer model

Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholineco-n-butyl methacrylate) in an orthotopic bladder cancer model
6    42    1
Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder

Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder
8    52    1
BLADDER CANCER – FROM BASIC SCIENCE TO ROBOTIC SURGERY

BLADDER CANCER – FROM BASIC SCIENCE TO ROBOTIC SURGERY

470    82    0
Schistosomiasis and Cancer in Egypt: Review

Schistosomiasis and Cancer in Egypt: Review
6    56    0
Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: A systematic review and meta-analysis

Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: A systematic review and meta-analysis
13    50    0
Risk of second primary Cancer among bladder Cancer patients: A populationbased cohort study in Korea

Risk of second primary Cancer among bladder Cancer patients: A populationbased cohort study in Korea
9    86    1
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
9    75    1
Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling

Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling
13    44    1